Human PD-L1 ELISA kit
Hakarel
About This Product
PD-L1 can be quantified to high sensitivity (sensitivity; 1pg/ml) from the blood sample and cell culture supernatant.
Cancer cells are expressed on the surface of PD-L1 (program cell death ligand-1) for PD-1 receptor expressed on the surface of activation T cells, and suppresses T cell activity through PD-1/PD-L1 binding to avoid the immune monitoring mechanism.
In recent years, these immune monitoring organizations have been applied to cancer treatment, and anti-PD-1 antibody drugs and anti-PD-L1 antibody drugs have been developed to enhance the activation of T cells by inhibiting this bond, and their clinical effects and safety have been confirmed in various solid cancers.
However, although the treatment resistance after the initial effect was observed, it was hardly understood the tolerance mechanism against anti-PD-L1 antibody drugs.
Recently, anti-PD-L1 resistant NSCLC patients have identified two unique secretion PD-L1 spracing variants that are missing the film penetration domain.
It is suggested that the secretion PD-L1 spracing variant acts as a "decoy" to induce the resistance to PD-L1 inhibitors, and the level of plasma (exosomation-free) or pleural water-soluble PD-L1 level is healthy in patients with the secreted PD-L1 spracing variant detected. It was higher than a patient without a donor or secreted PD-L1 mutant.
It also suggests that the blood concentration of the soluble PD-L1 may predict the clinical pathological characteristics, treatment reactions, and survival of cancer patients.
This kit can quantify the human PD-L1 in the sample with high sensitivity by the one-step sandwich method using high-performance antibodies for PD-L1, an immune checkpoint related molecule.
feature
・ Human PD-L1 can be detected with high sensitivity with the 1step elisa method.
・ No special device is required, and you can measure if you have a normal plate reader.
-
-
Product
Human PD-L1 ELISA kit